My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Johnson & Johnson (NY:JNJ)

226.71 -4.09 (-1.77%)

Official Closing Price Updated: 7:00 PM EDT, May 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Smooth Investing When the Ride Is Bumpy ↗

April 11, 2026

Diversification is a winning strategy for the long term, especially in a volatile market.

Via The Motley Fool

The $100 Billion Pivot: Why Johnson & Johnson Is My Top Dividend King to Buy in 2026 ↗

April 11, 2026

This stock might help you sleep more easily at night.

Via The Motley Fool

4 Stocks That Can Fund Decades of Passive Income -- Buy Them While They're Down ↗

April 11, 2026

These defensive consumer stocks are flashing buy signals while the market chases AI hype.

Via The Motley Fool

Topics Artificial Intelligence

Johnson & Johnson (NYSE:JNJ) Stands Out as a Quality Dividend Stock for Reliable Income ↗

April 01, 2026

Via Chartmill

Stocks Rallied After President Donald Trump's Ceasefire in Iran. Here's How to Invest Now. ↗

April 11, 2026

Moves made now could position your portfolio for success over time.

Via The Motley Fool

Topics Government Stocks

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

April 10, 2026

From Johnson & Johnson

Via Business Wire

Could Buying This Dividend Pharma Stock Today Set You Up for Life? ↗

April 09, 2026

This Dividend King drug maker's dividend yield is roughly twice that of the S&P 500 index.

Via The Motley Fool

Topics Stocks

Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value

April 09, 2026

Via Investor Brand Network

Topics Artificial Intelligence

The Teleflex Pivot: Inside the $1 Billion Share Buyback and Strategic Breakup

April 09, 2026

Disclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories...

Via Finterra

Topics Economy World Trade

ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue

April 09, 2026

Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall...

Via Finterra

Topics Economy World Trade

Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value

April 09, 2026

From AINewsWire

Via GlobeNewswire

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

April 09, 2026

JNJ (NYSE: JNJ) to release Q1 earnings before bell on April 14. Analysts expect $2.67/share & $23.6B revenue. FDA approves TECNIS PureSee lens.

Via Benzinga

These 3 Beaten-Down Stocks Haven't Been This Cheap in Over a Decade ↗

April 08, 2026

Buying stocks at incredibly low valuations often comes with risk, but it may also result in massive returns.

Via The Motley Fool

Topics Economy World Trade

This Healthcare Stock Has No Debt and a Near-Monopoly in Its Market ↗

April 07, 2026

The company is a picture of financial stability.

Via The Motley Fool

Martin Capital Dumps $4.5 Million in Robert Half Shares After a Brutal Year for the Staffing Sector ↗

April 07, 2026

Robert Half provides staffing and consulting services to global clients across accounting, finance, IT, legal, and creative sectors.

Via The Motley Fool

Topics Regulatory Compliance

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

April 07, 2026

From Johnson & Johnson

Via Business Wire

You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗

April 07, 2026

Could this player be heading into a new era of growth?

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System

April 06, 2026

ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval...

Via MarketMinute

Topics Artificial Intelligence

Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"

April 06, 2026

ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that...

Via MarketMinute

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

April 06, 2026

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...

Via MarketMinute

Topics Economy World Trade

Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check

April 06, 2026

Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,...

Via MarketMinute

Better Healthcare Stock to Own in a Recession: Defensive or Growth? ↗

April 04, 2026

The answer to the question might surprise many investors. It pays to be open-minded about risk.

Via The Motley Fool

Topics Economy Energy

JEPI vs. JEPQ: Which Is the Better Buy in April? ↗

April 04, 2026

These two high-yield heavyweights offer very different approaches.

Via The Motley Fool

Topics Bonds ETFs Economy

Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

April 03, 2026

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

Via Barchart.com

Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability

April 02, 2026

The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided...

Via MarketMinute

Topics Economy Retirement

This Healthcare Stock Barely Flinches During Market Sell-Offs ↗

April 02, 2026

Shares of Johnson & Johnson have fallen by less than 2% over the past month, while the S&P 500 has fallen by more than 7%.

Via The Motley Fool

Topics Economy Stocks

Stagflation Fears Are Back: These 3 Stocks Can Help You Ride Out the Storm ↗

April 02, 2026

These blue-chip stocks can make investors money if stagflation returns -- and also if it doesn't.

Via The Motley Fool

Topics Economy

The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future

April 01, 2026

As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed...

Via Finterra

Topics Artificial Intelligence Earnings Economy

Volatility Is Spiking. Here Are 3 Dividend Stocks You Can Buy Without Hesitation. ↗

April 01, 2026

These dividend stocks are ones you can rest peacefully at night owning.

Via The Motley Fool

Topics Economy

The Dividend King That's Raised Its Payout for 63 Consecutive Years ↗

March 31, 2026

This healthcare leader can weather almost any storm.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.